Colchicine to Help Prevent Irregular Heartbeat After Coronary Artery Bypass Surgery
Tests colchicine against placebo for irregular heartbeat after coronary artery bypass surgery in adults.
Plain-language title generated from the registry record
Registry title: Colchicine for the Prevention of Post-Operative Atrial Fibrillation After Coronary Artery Bypass Grafting: A Single-Center, Strategy-Stratified, Randomized, Double-Blind, Placebo-Controlled Trial
Key facts
- Where
- Taipei, TaiwanSee the site
- Phase
- Phase 2/3
Where in Taiwan
- National Taiwan University HospitalTaipei, TaiwanNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- National Taiwan University Hospital
- Trial code
- NCT07611019
- Record updated
- 10 July 2026
- Original description
Post-operative atrial fibrillation after coronary artery bypass grafting (CABG)Read full original descriptionShow less
Randomized, Double-Blind, Placebo-Controlled Trial of Colchicine to Prevent Post-Operative Atrial Fibrillation After CABG With Strategy-Stratified Randomization
Post-operative atrial fibrillation after coronary artery bypass grafting (CABG)
Inclusion: Adults aged 20 years or older scheduled to undergo elective coronary artery bypass grafting (CABG), including either off-pump CABG or on-pump CABG; Ability to receive oral study medication before and after surgery; Provision of written informed consent before randomization.
Exclusion: Known hypersensitivity or previous severe adverse reaction to colchicine; Current use of strong CYP3A4 or P-glycoprotein inhibitors that cannot be safely discontinued or substituted; History of atrial fibrillation or atrial flutter before surgery; Severe renal impairment (estimated glomerular filtration rate <30 mL/min/1.73 m²) or chronic dialysis; Any condition judged by the investigators to interfere with study participation or safety assessment; Severe hepatic dysfunction; Pregnancy or breastfeeding.